arrow
F

Floris J. Pos

Netherlands Cancer Institute
H指数:44
被引数:6,354

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions (DESTINATION 2): protocol for a randomised, phase II/R-IDEAL2b trial

利用MR-Linac进行前列腺放射治疗的剂量递减(2次分割)(DESTINATION 2):一项随机、II/R-IDEAL2b期试验方案

2026-05-070
PRE
Acute adverse events in the DESTINATION 1 trial: A prospective prostate SBRT dose de-escalation feasibility study

DESTINATION 1试验中的急性不良事件:一项前瞻性前列腺SBRT剂量递减可行性研究

2026-01-060
OAAI
Primary endpoint analysis of the phase II DESTINATION-MRL trial for patients with intermediate-risk prostate cancer

DESTINATION-MRL试验的II期研究中,针对中危风险前列腺癌患者的首要终点分析

2025-11-260
OAAI
Hypofractionated Dose Escalation versus Conventionally Fractionated Radiotherapy for Patients with Intermediate- and High-risk Localized Prostate Cancer: Long-term Results of the HYPRO trial

对于局限性中危和高危前列腺癌患者,低分割剂量递增与常规分割放射治疗比较:HYPRO试验的长期结果

2025-10-150
PRE
Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial

立体定向放射治疗对前列腺内肿瘤进行局部增强,以治疗中危和高危前列腺癌: 在hypo-flame试验中的5年疗效和毒性

2024-12-011
PRE
Development of Prostate Bed Delineation Consensus Guidelines for Magnetic Resonance Image-Guided Radiotherapy and Assessment of Its Effect on Interobserver Variability
2024-02-013
PRE
Risk Modeling for Individualization of the FLAME Focal Boost Approach in External Beam Radiation Therapy for Patients With Localized Prostate Cancer
2024-01-014
PRE
From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: Primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial

从每周一次到半每周一次的全前列腺立体定向放射治疗和局部增强: 多中心II期低火焰2.0试验的主要终点分析

2023-08-0112
PRE